SELLAS Life Sciences

SLSPhase 3

SELLAS Life Sciences is dedicated to advancing targeted immunotherapies for cancer, with a core focus on its WT1-targeting platform. Its most advanced candidate, galinpepimut-S, is in Phase 2/3 development for acute myeloid leukemia (AML) and malignant pleural mesothelioma. The company operates as a lean, clinical-stage organization, leveraging its expertise in antigen-specific vaccines to address significant unmet medical needs in oncology.

Market Cap

$854.6M

Employees

11-50

Focus

Biotech

SLS · Stock Price

USD 4.762.06 (-30.21%)

Historical price data

AI Company Overview

Technology Platform

Platform for developing peptide-based cancer vaccines targeting specific tumor-associated antigens, with a core focus on the Wilms Tumor 1 (WT1) protein to stimulate T-cell mediated anti-tumor immunity.

Pipeline Snapshot

8 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Galinpepimut-S + Azacitidine + Venetoclax + Decitabine + Cytarabine + GM-CSF	Acute Myeloid Leukemia	Phase 3
Herceptin + NeuVax vaccine + GM-CSF	Breast Cancer	Phase 2
NeuVax vaccine + Trastuzumab + GM-CSF	Breast Cancer	Phase 2
Galinpepimut-S + GM-CSF	Acute Myeloid Leukemia	Phase 2
Galinpepimut-S + Montanide + GM-CSF + Montanide + GM-CSF	Malignant Pleural Mesothelioma	Phase 2

Funding History

Total raised: $80M

PIPE$40MBVF PartnersMar 15, 2022

PIPE$25MPerceptive AdvisorsDec 15, 2020

IPO$15MUndisclosedFeb 14, 2018

Opportunities

Major opportunities include successful Phase 3 data for GPS in AML, which could lead to a new maintenance therapy in a large market, and expansion into additional WT1-positive cancers.

The HER2-low breast cancer space offers a substantial addressable population for NPS in combination with standard care.

Risk Factors

Key risks are clinical trial failure, particularly in late-stage studies, which could critically devalue the company.

Persistent financial constraints may limit trial progress or force dilutive financing.

Intense competition from larger biopharma firms in all target indications poses a significant commercial threat.

Competitive Landscape

SELLAS competes with large oncology-focused biopharma (e.g., AstraZeneca, Merck, Pfizer) and other biotechs in AML, mesothelioma, and breast cancer. Its primary differentiation is the focused, off-the-shelf vaccine approach targeting the WT1 antigen, aiming for a durable T-cell response, which is distinct from checkpoint inhibitors, ADCs, or chemotherapy.

Publications

Pipeline